Anti-proliferative effects of paroxetine alone or in combination with sorafenib in HepG2 cells

• Autores principales: Yaprak Donmez Cakil (Autor), Zeynep Gunes Ozunal (Autor), Damla Gokceoglu Kayali (Autor), Ranan Gulhan Aktas (Autor), Esra Saglam (Autor)
• Formato: Libro
• Publicado: Universidade de São Paulo, 2023-01-01T00:00:00Z.
• Materias: article
• Acceso en línea: Connect to this object online.

Abstract Hepatocellular carcinoma (HCC) is a common cause of cancer-related death. Sorafenib is the first approved drug for the treatment of advanced HCC. Depression is frequent in cancer patients. Moreover, sorafenib might exert depression as an adverse drug reaction and paroxetine, a selective ser...